Last reviewed · How we verify

NCT04477837

Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants

Completed Last updated 21 August 2024
What this trial tests

trial testing Apixaban 5 MG in Heavy Menstrual Bleeding in 84 participants. Completed in 15 June 2024.

Timeline
15 October 2020
Primary endpoint
31 May 2024
15 June 2024

Quick facts

Lead sponsorCardioangiologisches Centrum Bethanien
StatusCompleted
Study typeOBSERVATIONAL
Enrollment84
Start date15 October 2020
Primary completion31 May 2024
Estimated completion15 June 2024
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Cardioangiologisches Centrum Bethanien

Who can join

Adults 18 to 50, female only, with Heavy Menstrual Bleeding. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective comparison of the incidence of heavy menstrual bleeding (HMB) in women of reproductive age treated with direct oral anticoagulants (DOACs)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Apixaban 5 MG

Trials testing the same drug.

Other recruiting trials for Heavy Menstrual Bleeding

Currently open trials in the same condition.

Other Cardioangiologisches Centrum Bethanien trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04477837.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing